The takeaway
Axsome Therapeutics Inc shows a pronounced seasonal pattern over 10 years of data — strongest in December (+22.2%) and softest in February (−5.3%).
Right now
In July, the stock has fallen 40% of years, averaging −3.1%, roughly 5.3 pts behind the S&P 500.
The full picture
Axsome Therapeutics Inc's most dependable month has been December, higher in 8 of 10 years; February has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+21.2 pts); it has trailed the market most in May (−5.5 pts).
“vs S&P” is Axsome Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Axsome Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 80% of the time versus 80% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: December, up in 8 of 10 Decembers while the other eleven tend to blur together.
The headline flatters a touch — its +22.2% average sits well above the +11.0% a typical year delivers, the work of a few big Decembers. That reliability comes with real swings, mind — even December ranges by 47.7% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +21.2 points above the index. That consistency sets it apart from the field, where the average stock manages December only about 58% of the time.
A few other months pull their weight: April, June, and November have also closed higher more often than not. At the other end of the calendar, February has been the soft spot — the weakest of 4 months that average a loss (−5.3%), and the edge isn't year-round — the stock has trailed the S&P 500 in May, July, and February. Its roughest month on record was a −49.0% August in 2021 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Decembers run ahead of the earlier years.
The takeaway is less about when to buy than what to expect: December aside, the stock's months offer little reliable tilt. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (December, +22.2%) has run well ahead of its worst (February, −5.3%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +22.2% and closing higher in 8 of 10 years since 2016.
It's the weakest, averaging −5.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade